The Clinical Features Of 70 Cases Of Acute Promyelocytic Leukemia And The Curative Effect Analysis

Objective: To get the picture of the clinical characteristics of APL patients who were received between 2005 and 2015.To compare the recent and forward curative effect between two groups.one group uses ATRA 、ATO combined with idarubicin and the other group uses ATRA、ATO combined with daunorubicin.Methods: Performed retrospective analysis of APL patients who were received between 2005 and 2015. Compare clinical characteristics of the patients.SPSS was used to analysis the data.Results: 1.70 patients ’clinical characteristics:There are 32(45.7%) male patients,38 female petients.The youngest patient is 16 years old,the oldest patient is 71 years old. The mean age is 34.53±14.76 years old.65(92.86%) patiens see the doctor because of bleeding symptom.There are 20(28.6%) high risk patients,50(72.1%)low/moderate risk patients.The proportion of promyelocyte in the marrow is above 80%.All the patients’ POX test are strongly positive.68 patients are classified as coarse particle type,2 patients are classified as fine partical type.64(91.43%)patients have classic chromosome abnormality. There 14 patients of S type,25 patients of L type.All of the patients express CD33.Many people express CD13、CD38、c MPO、CD117、CD64.2.Compare the recent and forward curative effect between the two groups.The median time of getting complete remission of the group uses ATRA 、ATO combined with idarubicin is 28 days and The median time of getting complete remission of the mother group is 35 days,P=0.038.3.Infection rate of the group uses ATRA 、ATO combined with idarubicin is 33.3%,the other group is 68.3%,P=0.031. And the incidence of less than the other group.P=0.030.Conclusion:1. APL has specific chromosome,all ages of people can suffer from the disease.Most of them of 20~60 years old.Bleeding is the common performance.Bone marrow cell is given priority to with coarse particles.Patients had a high expression of CD33、CD13、CMPO、CD38、CD117、CD64.2.Patients treated by ATRA 、ATO combined with idarubicin has less days ach ieving complete commission and has low incidence of hepatic toxicity and infec tion.There is no differences in the matters of complete remission rate、early death rate、overall survival rate of 3 years between two groups.There was no difference in the survival analysis.There is no differences in the matters of incidence of card iac toxicity and the incident of retinoic acid syndrome.